Literature DB >> 7670730

Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

D R Blue1, D W Bonhaus, A P Ford, J R Pfister, N A Sharif, I A Shieh, R L Vimont, T J Williams, D E Clarke.   

Abstract

1. The present study characterizes and classifies alpha 1-adrenoceptor-mediated vasoconstriction in the isolated perfused kidney of rat using quantitative receptor pharmacology and compares the results to radioligand binding studies (made in cloned alpha 1-adrenoceptor subtypes, native alpha 1A-adrenoceptors in submaxillary gland of rat, and alpha 1A-adrenoceptors in several other tissues of rat). 2. Concentration-effect curves to noradrenaline in the presence of 5-methyl-urapidil were biphasic, indicating alpha 1-adrenoceptor heterogeneity. The alpha 1-adrenoceptor subtype mediating the first phase (low affinity for 5-methyl-urapidil) could not be 'isolated' for detailed pharmacological characterization but was defined by a sensitivity to inhibition by chloroethylclonidine and an inability of methoxamine to activate the site. Additionally, vasoconstriction mediated by this alpha 1-adrenoceptor subtype or subtypes was abolished by nitrendipine (1 microM), thereby allowing characterization of the second, high affinity site for 5-methyl-urapidil. 3. The following antagonists interacted competitively with noradrenaline at the alpha 1-adrenoceptor for which 5-methyl-urapidil exhibits high affinity (pKB value): WB 4101 (10.3) > prazosin (9.5) approximately HV 723 (9.3) approximately 5-methyl-urapidil (9.2) > phenotolamine (8.6) > spiperone (pA2 = 8.1) approximately oxymetazoline (7.9). In contrast, insurmountable antagonism was seen with S(+)- and R(-)-niguldipine, the S(+)-isomer being approximately 30 fold more potent than the R(-)-isomer. Receptor protection experiments indicated that S(+)-niguldipine interacted directly with alpha 1-adrenoceptors. Dehydroniguldipine acted as a competitive antagonist (pKB = 9.0). Thus, the results with antagonists define the alpha 1-adrenoceptor as an alpha 1A-adrenoceptor. 4. An agonist 'fingerprint' was constructed in the presence of nitrendipine to define further the alpha 1A-adrenoceptor. The following order and relativity of agonist potency was obtained: cirazoline (1) approximately adrenaline (2) > noradrenaline (5) > phenylephrine (23) approximately amidephrine (31) > methoxamine (71) >> isoprenaline (1456) approximately dopamine (2210). 5. A high correlative association was shown between the affinity of antagonists obtained functionally in the isolated perfused kidney of rat and pKi values obtained from binding experiments with the cloned bovine alpha 1C-adrenoceptor (R2 = 0.85), native alpha 1A-adrenoceptors in submaxillary gland of rat (R2 = 0.79), and alpha 1A-adrenoceptors from several other tissues of rat (values taken from the literature, R2 = 0.89). 6. The present study demonstrates that the alpha 1A-adrenoceptor is the predominant alpha 1-adrenoceptor subtype mediating vasoconstrictor responses to exogenously administered noradrenaline in the isolated perfused kidney of rat. More importantly, alpha 1A-adrenoceptors mediating vasoconstrictor responses to noradrenaline exhibited a pharmacological equivalency to the cloned bovine alpha 1 c-adrenoceptor. Thus,definitive functional pharmacological data are provided for equating the two receptors and support results derived recently from molecular and radioligand binding studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670730      PMCID: PMC1908326          DOI: 10.1111/j.1476-5381.1995.tb15875.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  62 in total

1.  Pharmacologic characterization of cloned alpha 1-adrenoceptor subtypes: selective antagonists suggest the existence of a fourth subtype.

Authors:  D A Schwinn; J W Lomasney
Journal:  Eur J Pharmacol       Date:  1992-12-01       Impact factor: 4.432

2.  The adrenoceptor agonist, SDZ NVI 085, discriminates between alpha 1A- and alpha 1B-adrenoceptor subtypes in vas deferens, kidney and aorta of the rat.

Authors:  M Eltze; R Boer
Journal:  Eur J Pharmacol       Date:  1992-12-02       Impact factor: 4.432

3.  Comparison of alpha 1-adrenoceptors between rat brain and spleen.

Authors:  H Tsuchihashi; K Maruyama; S Baba; F Mano; J Kinami; T Nagatomo
Journal:  Jpn J Pharmacol       Date:  1991-08

4.  Vasodilatation elicited by 5-HT1A receptor agonists in constant-pressure-perfused rat kidney is mediated by blockade of alpha 1A-adrenoceptors.

Authors:  M Eltze; R Boer; K H Sanders; N Kolassa
Journal:  Eur J Pharmacol       Date:  1991-09-04       Impact factor: 4.432

5.  Three distinct binding sites for [3H]-prazosin in the rat cerebral cortex.

Authors:  M Oshita; S Kigoshi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

6.  Regional distribution of alpha 1-adrenoceptor subtypes in rat kidney.

Authors:  F Feng; W A Pettinger; P W Abel; W B Jeffries
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

7.  5-Methylurapidil may discriminate between alpha 1-adrenoceptors with a high affinity for WB4101 in rat lung.

Authors:  Y Hiramatsu; R Muraoka; S Kigoshi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

8.  Evidence for a noradrenergic innervation to alpha 1A-adrenoceptors in rat kidney.

Authors:  D R Blue; R L Vimont; D E Clarke
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

9.  Characterization of [3H]YM617, R-(-)-5-[2-[[2[ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]- propyl]-2-methoxybenzenesulfonamide HCl, a potent and selective alpha-1 adrenoceptor radioligand.

Authors:  H Yazawa; M Takanashi; K Sudoh; O Inagaki; K Honda
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

10.  Expression of renal alpha 1-adrenergic receptor subtypes in established hypertension.

Authors:  C A Jackson; M C Michel; P A Insel
Journal:  J Cardiovasc Pharmacol       Date:  1992-06       Impact factor: 3.105

View more
  14 in total

1.  Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.

Authors:  R F Schäfers; B Fokuhl; A Wasmuth; H Schumacher; K Taguchi; C de Mey; T Philipp; M C Michel
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

2.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

3.  Interaction between alpha(1)- and alpha(2)-adrenoreceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries.

Authors:  Alexandra Sporkova; Alex Perez-Rivera; James J Galligan
Journal:  Eur J Pharmacol       Date:  2010-06-21       Impact factor: 4.432

4.  Evidence for involvement of alpha1D-adrenoceptors in contraction of femoral resistance arteries using knockout mice.

Authors:  Joseph Zacharia; Chris Hillier; Akito Tanoue; Gozoh Tsujimoto; Craig J Daly; John C McGrath; Allan MacDonald
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

5.  In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists.

Authors:  T J Williams; D R Blue; D V Daniels; B Davis; T Elworthy; J R Gever; M S Kava; D Morgans; F Padilla; S Tassa; R L Vimont; C R Chapple; R Chess-Williams; R M Eglen; D E Clarke; A P Ford
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Functional characterization of alpha(1)-adrenoceptor subtypes in human skeletal muscle resistance arteries.

Authors:  Y P Jarajapu; P Coats; J C McGrath; C Hillier; A MacDonald
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

7.  A possible structural determinant of selectivity of boldine and derivatives for the alpha 1A-adrenoceptor subtype.

Authors:  Y Madrero; M Elorriaga; S Martinez; M A Noguera; B K Cassels; P D'Ocon; M D Ivorra
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

8.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

9.  Analysis of the effects of alpha 1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery.

Authors:  P H Van der Graaf; N P Shankley; J W Black
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  The contribution of adrenoceptor subtype(s) in the renal vasculature of diabetic spontaneously hypertensive rats.

Authors:  A Armenia; A S Munavvar; N A Abdullah; A Helmi; E J Johns
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.